Charles Schwab Investment Management Inc. Acquires 162,628 Shares of Senseonics Holdings, Inc. $SENS

Charles Schwab Investment Management Inc. raised its holdings in Senseonics Holdings, Inc. (NYSE:SENS) by 4.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,502,326 shares of the company’s stock after acquiring an additional 162,628 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.54% of Senseonics worth $2,298,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. IFP Advisors Inc boosted its position in shares of Senseonics by 120.9% during the first quarter. IFP Advisors Inc now owns 47,500 shares of the company’s stock worth $31,000 after purchasing an additional 26,000 shares in the last quarter. Smith Salley Wealth Management bought a new position in shares of Senseonics during the first quarter worth $36,000. Ridgecrest Wealth Partners LLC boosted its position in shares of Senseonics by 160.9% during the first quarter. Ridgecrest Wealth Partners LLC now owns 300,000 shares of the company’s stock worth $197,000 after purchasing an additional 185,000 shares in the last quarter. Cambridge Investment Research Advisors Inc. boosted its position in shares of Senseonics by 679.9% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 289,919 shares of the company’s stock worth $190,000 after purchasing an additional 252,745 shares in the last quarter. Finally, Two Sigma Investments LP bought a new position in shares of Senseonics during the fourth quarter worth $36,000. 12.36% of the stock is owned by institutional investors.

Senseonics Stock Down 0.1%

Shares of SENS stock opened at $0.46 on Friday. The company has a current ratio of 2.47, a quick ratio of 2.38 and a debt-to-equity ratio of 59.17. Senseonics Holdings, Inc. has a 1 year low of $0.25 and a 1 year high of $1.40. The firm’s fifty day moving average price is $0.50 and its two-hundred day moving average price is $0.61. The firm has a market capitalization of $374.35 million, a P/E ratio of -3.53 and a beta of 0.88.

Analyst Upgrades and Downgrades

SENS has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $1.40 price target (up from $1.10) on shares of Senseonics in a research report on Tuesday, July 8th. TD Cowen initiated coverage on shares of Senseonics in a report on Tuesday, July 15th. They set a “buy” rating and a $1.25 price objective on the stock. Lake Street Capital upgraded shares of Senseonics to a “strong-buy” rating in a report on Thursday, July 17th. Barclays initiated coverage on shares of Senseonics in a report on Wednesday. They set an “overweight” rating and a $1.50 price objective on the stock. Finally, Wall Street Zen upgraded shares of Senseonics to a “sell” rating in a report on Monday, May 12th. Two analysts have rated the stock with a Strong Buy rating and three have issued a Buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $1.54.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.